Digest Network Come funziona
Network
/
Società
Ve
Non verificato

Verastem Oncology

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

71 comunicati stampa

Guarda tutti i comunicati
03/06/2026
Industria
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
27/05/2026
Eventi
Web e Social Network
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Verastem Oncology to Present at Jefferies Healthcare Conference
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
26/05/2026
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Mercato del lavoro
Verastem Oncology Appoints Michael P. Bailey to its Board of Directors
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
08/05/2026
On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
07/05/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
30/04/2026
Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
23/04/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
10/04/2026
Eventi
Fiere
Industria
Oncologia
Salute
Vetrine/Shopping
Medicina - Varie
Farmaceutica
Biotecnologia
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s Cancers
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
02/04/2026
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
17/03/2026
Eventi
Industria
Oncologia
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0